Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin

Kelly E. Faulk, Jenna M. Sopfe, Kristen Campbell, Deborah R. Liptzin, Arthur K. Liu, Anna R.K. Franklin, Carrye R. Cost

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Brentuximab vedotin (Bv) is becoming increasingly important in the treatment of Hodgkin lymphoma (HL), with improved outcomes and an overall favourable toxicity profile. However, Bv is associated with severe pulmonary toxicity when combined with bleomycin, suggesting that additive toxicity may be an important consideration. Furthermore, little has been published on tolerability in paediatric patients. We retrospectively evaluated the occurrence of pulmonary toxicity of Bv in 19 paediatric and young adult patients with relapsed or refractory HL. Patient characteristics, baseline health status, treatment regimens including cumulative doses of Bv, bleomycin, gemcitabine, radiation and carmustine, and the occurrence of pulmonary toxicity were collected. Seven (36·8%) of the 19 patients were treated with Bv. The odds of pulmonary toxicity were 4·0-fold higher (95% confidence interval 0·55–29·18) in patients exposed to Bv compared to unexposed patients in univariate analysis (P = 0·17). Similar results were found in multivariable analysis. Pulmonary toxicity occurred frequently in our cohort and was more common in patients who received Bv than in patients who did not receive Bv, although this was not statistically significant. Because patients with HL are exposed to a myriad of therapies with potential for pulmonary toxicity, continuing to evaluate the risk associated with Bv is critical.

Original languageEnglish
Pages (from-to)251-256
Number of pages6
JournalBritish Journal of Haematology
Issue number2
StatePublished - Oct 2018


  • brentuximab vedotin
  • oncology drugs
  • paediatric Hodgkin lymphoma
  • pulmonary toxicity
  • relapsed Hodgkin lymphoma


Dive into the research topics of 'Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin'. Together they form a unique fingerprint.

Cite this